alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › now

now

2 studies tagged now, dated 2018-09-01 to 2025-12-15. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. FDA-Approved Passive Immunization Treatments Against Aβ in Alzheimer’s Disease: Where Are We Now? 2025-12-15
  2. Diagnosis of neurodegenerative dementia: where do we stand, now? 2018-09-01

Studies

2 studies carry this tag.

Date range

2018 to 2025

Top journals

  • Annals of translational medicine 1
  • Preprints.org 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. FDA-Approved Passive Immunization Treatments Against Aβ in Alzheimer’s Disease: Where Are We Now?

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Preprints.org 2025-12-15 Treatments

    Alzheimer’s disease (AD) is a progressive neurodegenerative disorder marked by de-creased amyloid-β clearance, enhanced Aβ aggregation, an increased risk of amy-loid-related imaging abnormalities (ARIA), and blood-brain barrier (BBB) dysfunction.

  2. Diagnosis of neurodegenerative dementia: where do we stand, now?

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Annals of translational medicine 2018-09-01 Biomarkers

    After many years of large efforts made for understanding the pathogenesis of dementias, the early diagnosis of these degenerative diseases remains an open challenge.

All topic tags with their study counts